The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Concentra Group (CON) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Concentra Group is one of 1003 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Solventum (SOLV) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This health care company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 13.24%.For the last reported quarter, S ...

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for allegedly misleading investors and failing to disclose critical issues during the Class Period from February 28, 2023, to January 10, 2025 [1][3]. Company Overview - TransMedics Group, Inc. is a medical technology company based in Andover, Massachusetts, specializing in transplant services, including its Organ Care System (OCS), which is a portable organ preservation system [2]. Allegations - The lawsuit claims that TransMedics engaged in unethical practices, including using kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [3]. - It is also alleged that the company concealed safety issues and lacked proper safety oversight within its operations [3]. Impact of Revelations - On February 21, 2024, U.S. Rep. Paul Gosar accused TransMedics of misappropriating corporate resources, leading to a stock price drop of $2.18 per share (2.5%) to close at $84.81 on February 22, 2024 [4]. - Following a report from Scorpion Capital on January 10, 2025, which accused TransMedics of overbilling hospitals and providing rejected organs, the stock fell by $3.74 per share (5%) to close at $68.81, and then further declined by $4.76 per share (6.9%) to close at $64.05 on January 13, 2025 [5].

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Core Insights - Teladoc's shares have decreased by approximately 9.9% since the last earnings report, underperforming the S&P 500 [1] - Recent estimates for Teladoc have trended upward, with a consensus estimate shift of 6.15% [2] - Teladoc holds a VGM Score of A overall, with a Growth Score of B, a Momentum Score of D, and a Value Score of A [3] - The stock has a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [4] Industry Performance - Teladoc is part of the Zacks Medical Services industry, where CVS Health has seen a 4.8% increase in the past month [5] - CVS Health reported revenues of $97.71 billion for the last quarter, reflecting a year-over-year growth of 4.2% [5] - CVS Health's expected earnings for the current quarter are $1.62 per share, indicating a year-over-year increase of 23.7% [6]

Core Viewpoint - The collaboration between China Rehabilitation Research Center and Hebei Yanda Hospital aims to enhance rehabilitation services in the Beijing-Tianjin-Hebei region, focusing on integrating medical, educational, and research resources to improve the quality and accessibility of rehabilitation care for local residents [1][2]. Group 1: Strategic Collaboration - A tight-knit medical alliance agreement was signed to promote comprehensive strategic cooperation in various fields, including rehabilitation medical services, talent cultivation, and quality management [1]. - The partnership is expected to create a regional rehabilitation medical center and demonstration base, enhancing the overall rehabilitation service system for the local population [1][2]. Group 2: Development of Rehabilitation Services - The collaboration will strengthen the integrated model of medical care, elderly care, and rehabilitation, significantly improving the quality of rehabilitation services and laying the foundation for the silver economy [2]. - Hebei Yanda Hospital has established partnerships with several prestigious hospitals in Beijing, enhancing its rehabilitation capabilities and service offerings [2]. Group 3: Progress and Impact - By the end of 2024, a total of 30 cooperation agreements will be in place between medical institutions in Sanhe City and well-known hospitals in Beijing, with over 55,000 patients treated annually [3]. - The initiative aims to optimize the rehabilitation service landscape in the Beijing-Tianjin-Hebei region, facilitating the rational flow and sharing of rehabilitation medical resources [2].

Group 1: Company Performance - CVS Health closed at $67.91, with a 0.5% increase, lagging behind the S&P 500's 1.08% gain on the same day [1] - Over the past month, CVS shares gained 3.05%, outperforming the Medical sector's 0.21% gain and the S&P 500's 8.26% loss [1] Group 2: Earnings Projections - The upcoming earnings per share (EPS) for CVS Health is projected at $1.62, indicating a 23.66% increase year-over-year [2] - Revenue for the same quarter is estimated at $92.82 billion, reflecting a 4.95% rise from the previous year [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $5.88 per share and revenue at $387.86 billion, representing increases of 8.49% and 4.04% respectively from the prior year [3] - Recent analyst estimate revisions suggest a favorable outlook on CVS Health's business health and profitability [3] Group 4: Valuation Metrics - CVS Health has a Forward P/E ratio of 11.48, which is lower than the industry's average Forward P/E of 16.13 [6] - The company has a PEG ratio of 1.02, compared to the Medical Services industry's average PEG ratio of 1.42 [6] Group 5: Industry Ranking - The Medical Services industry, which includes CVS Health, holds a Zacks Industry Rank of 71, placing it in the top 29% of over 250 industries [7] - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [7]

Group 1 - Aurora Cannabis Inc. is currently ranked 2 (Buy) in the Zacks Rank system, indicating a strong potential for outperforming the market in the next one to three months [3] - The Zacks Consensus Estimate for Aurora Cannabis Inc.'s full-year earnings has increased by 2400% over the past 90 days, reflecting a significant improvement in analyst sentiment [3] - Year-to-date, Aurora Cannabis Inc. has returned approximately 3.8%, outperforming the average return of 3.4% for the Medical sector [4] Group 2 - Aurora Cannabis Inc. belongs to the Medical - Products industry, which consists of 83 individual stocks and is currently ranked 141 in the Zacks Industry Rank [5] - The average return for stocks in the Medical - Products industry this year is 6.1%, indicating that Aurora Cannabis Inc. is slightly underperforming its industry [5] - Concentra Group, another Medical stock, has outperformed the sector with a year-to-date return of 5.1% and also holds a Zacks Rank of 2 (Buy) [4][5]

Core Insights - The integration of hospital data in Beijing has significantly improved patient convenience, allowing for seamless access to medical records without the need for physical documents [1][2] - The Beijing Health Commission reports that 60 clinical test results are now recognized across 914 medical institutions in the Beijing-Tianjin-Hebei region, enhancing service standardization [1][2] - The implementation of "cloud services" by various medical institutions allows patients to access their medical imaging and test data via mobile apps, streamlining the process for follow-up and referrals [1][2] Summary by Categories - **Data Interconnectivity**: The ability for hospitals to access CT and test results from other institutions within three months enhances patient care and reduces the need for physical documentation [1][2] - **Clinical Test Recognition**: 60 clinical test results are mutually recognized across 914 medical institutions, which includes secondary and tertiary hospitals, independent labs, and private medical facilities [1][2] - **Cloud Services Adoption**: Many medical institutions are offering cloud services, enabling patients to retrieve their medical history and imaging data through mobile technology, facilitating easier follow-ups and referrals [1][2]

Core Viewpoint - ModivCare reported quarterly earnings of $0.19 per share, exceeding the Zacks Consensus Estimate of a loss of $0.10 per share, but down from $1.29 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was 290%, with a previous expectation of $0.59 per share, but the actual earnings were $0.45, resulting in a surprise of -23.73% [2] - ModivCare's revenues for the quarter ended December 2024 were $702.8 million, surpassing the Zacks Consensus Estimate by 0.51%, compared to $703.22 million in the same quarter last year [3] - The company has exceeded consensus revenue estimates two times in the last four quarters [3] Stock Performance - ModivCare shares have declined approximately 71.6% since the beginning of the year, while the S&P 500 has only decreased by 0.7% [4] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $715.67 million, and for the current fiscal year, it is $0.67 on revenues of $2.86 billion [8] Industry Outlook - The Medical Services industry, to which ModivCare belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [9]